Skip to main content

Table 1 Patient characteristics before BPA

From: Bilateral versus unilateral balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension

 

CTEPH (N = 92)

Age (years)

59 ± 12

Female (%)

63 (68%)

Number of BPA sessions/patient

2 (1, 3)

Total BPA sessions

210

Interval between BPA (days)

80 (48, 131)

Hemodynamics

 Heart rate

81 ± 13

 Mean RAP (mmHg)

7.4 ± 5.0

 Systolic PAP (mmHg)

75.5 ± 25.6

 Diastolic PAP (mmHg)

24.8 ± 9.0

 Mean PAP (mmHg)

43.0 ± 13.6

 PVR (Wood Unit)

10.3 ± 6.7

 Cardiac output (L/min)

4.1 ± 1.8

 Cardiac index (L/min/m2)

2.6 ± 1.1

 PASO2 (%)

62.5 ± 10.2

 MVSO2 (%)

93.9 ± 4.4

 NT-proBNP (pg/ml)

541.1 (120.0, 1823.8)

Exercise capacity

 WHO functional class (I/II/III/IV, %)

7/45/36/4 (7.6/48.9/39.1/4.3)

PAH targeted therapy (%)

50 (54.3%)

Riociguat

28 (30.4)

Macitentan

11 (12.0)

Treprostinil

10 (10.9)

Tadalafil

8 (8.7)

Sildenafil

7 (7.6)

Ambrisentan

5 (5.4)

Bosentan

4 (4.3)

Anticoagulation (%)

92 (100%)

Warfarin

19 (20.7)

Rivaroxaban

64 (69.6)

Dabigatran

9 (9.8)

  1. Continuous variables are expressed as mean ± standard deviation or median and interquartile range according to variable distribution. CTEPH chronic thromboembolic pulmonary hypertension, BPA balloon pulmonary angioplasty, RAP right atrium pressure, PAP pulmonary artery pressure, PVR pulmonary vascular resistance, PASO2 pulmonary arterial oxygen saturation, MVSO2 mixed venous oxygen saturation, NT-proBNP N-terminal pro-B-type natriuretic peptide, WHO World Health Organization